Welcome to our dedicated page for Lemaitre Vasculr news (Ticker: LMAT), a resource for investors and traders seeking the latest updates and insights on Lemaitre Vasculr stock.
LeMaitre Vascular, Inc. (NASDAQ: LMAT) is a provider of vascular devices, implants, and services for the treatment of peripheral vascular disease, with products developed for use by vascular surgeons. This news page aggregates company announcements, earnings releases, and other disclosures so readers can follow how LeMaitre’s vascular device business evolves over time.
In its regular quarterly updates, LeMaitre reports on net sales, gross margin, operating income, earnings per share, and geographic sales across the Americas, EMEA, and Asia Pacific. These releases often highlight which product categories, such as grafts, shunts, and catheters, are driving growth, and may call out specific products like the Artegraft biologic graft used in AV access and peripheral bypass. The company also discusses organic sales growth, adjusted profitability metrics, and the impact of pricing, volume, and manufacturing efficiencies.
Beyond earnings, LeMaitre issues news about dividends, share repurchase authorizations, and participation in healthcare and investor conferences hosted by firms such as Bank of America Securities, Wells Fargo, Morgan Stanley, and others. These events provide additional context on the company’s strategy, international expansion, and regulatory milestones, including launches of products like Artegraft in new markets.
Investors and observers can use this page to review historical press releases, monitor guidance updates, and see how management characterizes risks and opportunities in the peripheral vascular disease market. For ongoing coverage of LMAT news, this feed offers a centralized view of the company’s public communications and financial reporting.
LeMaitre Vascular (Nasdaq:LMAT) said management will participate in five investor conferences in March 2026, including presentations and 1x1 meetings.
Events:
- Leerink Partners Global Healthcare Conference — Mar 10, 2026, W South Beach, Miami, presentation 1:00 PM EDT
- Citizens Life Sciences Conference — Mar 11, 2026, Eden Roc Miami Beach, presentation 1:40 PM EDT
- Barclays Annual Global Healthcare Conference — Mar 12, 2026, available for 1x1 meetings
- KeyBanc Capital Markets Healthcare Forum — Mar 17, 2026, virtual, presentation 3:45 PM EDT
- 38th Annual ROTH Conference — Mar 22-24, 2026, available for 1x1 meetings and possible presentation
LeMaitre Vascular (Nasdaq: LMAT) reported Q4 2025 results with $64.5mm sales (+16%, +15% organic), gross margin 71.7% (+240 bps), operating income $18.8mm (+47%) and diluted EPS $0.68 (+39%). Cash rose to $359.1mm. The board approved a 25% dividend increase to $0.25/share and a $100mm repurchase authorization. Management guided FY2026 sales to a $276–$284mm range (mid $280mm, +12%) and mid op income of $77.8mm (adj. +21%).
Q4 growth was broad-based with grafts, valvulotomes and carotid shunts up and international strength in EMEA and APAC. Q1 2026 mid-sales guidance is $66.6mm (+11%).
LeMaitre Vascular (Nasdaq:LMAT) will release fourth-quarter 2025 financial results on February 25, 2026 after the market close. A conference call is scheduled the same day at 5:00 PM EST to review results, business highlights, and company outlook. The live audio webcast and replay will be available at the company investor website, and registrants receive dial-in details and a PIN.
LeMaitre Vascular (Nasdaq:LMAT) announced management will participate in three investor conferences in Nov–Dec 2025.
- Jefferies London Healthcare Conference — Tuesday, November 18, 2025 at 8:00 AM GMT at Waldorf Hilton, London; presenter: Dorian LeBlanc, CFO.
- Wolfe Research 7th Annual Healthcare Conference — Wednesday, November 19, 2025 at 10:40 AM ET at Wolfe NYC Offices, New York; presenter: David Roberts, President.
- Piper Sandler 37th Annual Healthcare Conference — Thursday, December 4, 2025 at 3:20 PM ET at Lotte Palace, New York; presenter: Dorian LeBlanc, CFO.
LeMaitre Vascular (Nasdaq: LMAT) reported Q3 2025 results and raised guidance on Nov. 6, 2025. Q3 sales were $61.0mm (+11% overall, +12% organic). GAAP operating income was $20.3mm (+54%) and diluted EPS was $0.75 (+54%); non-GAAP adjusted operating income was $16.9mm (+29%) and adjusted EPS was $0.62 (+27%). Adjusted gross margin was 70.8% (up 300 bps). Cash rose by $23.6mm sequentially to $343.1mm. Growth drivers: grafts +23%, shunts +18%, Artegraft +33% (international launch). Regional sales: EMEA +18%, Americas +10%, APAC +4%. The board declared a quarterly dividend of $0.20/share payable Dec. 4, 2025, and authorized a $75.0mm share repurchase program through Feb. 17, 2026. Guidance: FY 2025 mid‑sales of $248mm (+13%) and adjusted full‑year operating income mid of $63.7mm.
LeMaitre Vascular (NASDAQ:LMAT) will release its third quarter 2025 financial results on Thursday, November 6, 2025 after the market close. A conference call to discuss results, business highlights, and outlook is scheduled the same day at 5:00 PM EST. Investors can register for live dial‑in access and a PIN or listen via a live audio webcast and replay at the company's investor site.
LeMaitre Vascular (Nasdaq:LMAT) announced its participation in four upcoming investor conferences in September 2025. CFO Dorian LeBlanc will represent the company at the Wells Fargo Healthcare Conference (Sept 3), Cantor Global Healthcare Conference (Sept 4), Morgan Stanley Global Healthcare Conference (Sept 9), and the virtual Barrington Research Fall Investment Conference (Sept 16).
LeMaitre Vascular (Nasdaq: LMAT) reported strong Q2 2025 financial results with sales reaching $64.2 million, up 15% year-over-year. The company achieved notable performance metrics including a gross margin of 70.0% (up 110 bps), operating income of $16.1 million (up 12%), and earnings per diluted share of $0.60 (up 16%).
Growth was driven by strong performance in catheters (+27%) and grafts (+19%), with robust regional sales increases in EMEA (23%), Americas (12%), and APAC (12%). The company raised its 2025 guidance, announced a $0.20 quarterly dividend, and maintains an active $75.0 million share repurchase program through February 2026.
LeMaitre Vascular (Nasdaq:LMAT) has scheduled its second quarter 2025 financial results announcement for Tuesday, August 5, 2025, after market close. The company will host a conference call at 5:00 PM EDT on the same day to discuss quarterly results, business highlights, and future outlook.
Investors can access the live call by registering online, after which they will receive dial-in information and a PIN. Additionally, an audio webcast will be available both live and for replay through the company's investor relations website at ir.lemaitre.com.
LeMaitre Vascular (NASDAQ:LMAT) announced that its President, David Roberts, will present at the Bank of America Securities 2025 Healthcare Conference. The presentation is scheduled for Tuesday, May 13, 2024, at 5:00 PM PDT and will take place at the Encore at the Wynn Hotel in Las Vegas, NV.